TRAIL及其受体DR5、DcR1在宫颈癌中的表达  

Expressions of TRAIL and its death receptor in tissue of cervical carcinoma

作　　者：褚静[1] 荆亚茹 贾敏[1] 

机构地区：[1]西安医学院护理系,陕西西安710021

出　　处：《现代肿瘤医学》2009年第9期1749-1751,共3页Journal of Modern Oncology

摘　　要：目的:探讨TRAIL及其受体DR5、DcR1在宫颈癌中的表达及其临床意义。方法:应用免疫组化SP法对10例正常宫颈组织、18例宫颈上皮内瘤变(CIN)组织和40例宫颈癌组织中TRAIL、DR5及DcR1的表达情况进行检测,并结合患者年龄、肿瘤分化程度、组织类型、有无淋巴结转移等临床病理因素进行分析。结果:TRAIL及DcR1在正常宫颈组织中的表达高于宫颈癌组织;宫颈癌组织中,TRAIL阳性表达随组织学分级降低而降低;DR5在正常宫颈、CIN和宫颈癌组织中的表达呈递增趋势。结论:TRAIL、DR5及DcR1的异常表达在宫颈癌变过程中起一定的作用。Objective：To investigate the expression of TNF- related apoptosis inducing ligand （TRAIL） and its rceptor DR5 and DcR1 in cervical carcinoma. Methods： Immunohistochemical method was used to detect the expressions of TRAIL and its rceptor DR5 and DcR1 in 40 samples of cervical carcinoma, 18 samples of cervical intraepithelial neoplasia（CIN） ,and 10 samples of normal cervical tissues. Results：The expressions of TRAIL and DcR1 in normal cervical tissues were significantly higher than those in cervical carcinoma tissues, there was a significant difference between TRAIL expression and histologic grades, the lower expression rate of TRAIL was found in poorer differentiated tumors. Conclusion：The deregulation of TRAIL and its rceptor DR5 and DcR1 suggest a possible functional role in cervical carcinogenesis.

关 键 词：宫颈癌 TRAIL DCR1 DR5 凋亡 

分 类 号：R737.33[医药卫生—肿瘤]